Published in Vaccine on January 29, 2010
Clinical applications of DNA vaccines: current progress. Clin Infect Dis (2011) 1.65
Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines (2012) 1.44
Traditional and new influenza vaccines. Clin Microbiol Rev (2013) 1.22
H5N1 vaccines in humans. Virus Res (2013) 1.16
Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol (2011) 1.13
A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses. PLoS One (2011) 1.08
Vaccines: from empirical development to rational design. PLoS Pathog (2012) 1.01
Virus-like particles as universal influenza vaccines. Expert Rev Vaccines (2012) 0.93
M2e-Based Universal Influenza A Vaccines. Vaccines (Basel) (2015) 0.93
A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther (2014) 0.92
Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus. PLoS One (2011) 0.92
Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. J Gen Virol (2012) 0.89
Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines. Protein Cell (2010) 0.89
Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia. Hum Vaccin Immunother (2013) 0.86
Novel viral vectored vaccines for the prevention of influenza. Mol Med (2012) 0.83
Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans. Hum Vaccin Immunother (2015) 0.83
Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases. Clin Exp Vaccine Res (2015) 0.83
HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine. Viruses (2014) 0.82
Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus. Hum Vaccin Immunother (2012) 0.82
Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head. Vaccines (Basel) (2015) 0.81
Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines. Hum Vaccin Immunother (2013) 0.81
Recombinant influenza vaccines. Acta Naturae (2012) 0.80
Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine. Gene Ther (2015) 0.80
Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins. J Virol (2013) 0.79
Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge. PLoS One (2014) 0.79
A noninflammatory immune response in aged DNA Aβ42-immunized mice supports its safety for possible use as immunotherapy in AD patients. Neurobiol Aging (2014) 0.79
A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus. Virol J (2010) 0.79
Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses. Future Virol (2013) 0.78
Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives. Pharmaceutics (2014) 0.78
Fusion of antigen to a dendritic cell targeting chemokine combined with adjuvant yields a malaria DNA vaccine with enhanced protective capabilities. PLoS One (2014) 0.78
Fast vaccine design and development based on correlates of protection (COPs). Hum Vaccin Immunother (2014) 0.77
Phase 1 study of pandemic H1 DNA vaccine in healthy adults. PLoS One (2015) 0.77
A polyvalent influenza DNA vaccine applied by needle-free intradermal delivery induces cross-reactive humoral and cellular immune responses in pigs. Vaccine (2016) 0.76
Immunogenicity and Protective Efficacy of Brugia malayi Heavy Chain Myosin as Homologous DNA, Protein and Heterologous DNA/Protein Prime Boost Vaccine in Rodent Model. PLoS One (2015) 0.76
Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis. Vaccine (2015) 0.76
Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities? Mol Cell Ther (2013) 0.75
Recent outbreaks of highly pathogenic avian influenza viruses in South Korea. Clin Exp Vaccine Res (2017) 0.75
Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis (2017) 0.75
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34
Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med (2002) 3.86
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis (2005) 3.79
Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med (2011) 3.78
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A (2012) 2.96
Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol (2010) 2.63
Dose-related effects of smallpox vaccine. N Engl J Med (2002) 2.55
Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis (2012) 2.55
Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant (2005) 2.54
Diagnostic error in medicine: analysis of 583 physician-reported errors. Arch Intern Med (2009) 2.50
Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis (2008) 2.27
The immunogenetics of smallpox vaccination. J Infect Dis (2007) 2.23
A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis (2012) 2.08
Flow-cytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functions. J Infect Dis (2005) 1.84
Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis (2011) 1.71
The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine (2007) 1.68
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine (2007) 1.67
Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine. J Clin Microbiol (2003) 1.63
Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China. Clin Ther (2011) 1.60
Response to smallpox vaccine in persons immunized in the distant past. JAMA (2003) 1.59
H1 family histones in the nucleus. Control of binding and localization by the C-terminal domain. J Biol Chem (2005) 1.59
Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults. J Infect Dis (2007) 1.56
Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J (2004) 1.52
The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses (2010) 1.47
Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. AIDS Res Hum Retroviruses (2007) 1.46
Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination. J Infect Dis (2004) 1.42
GDF6, a novel locus for a spectrum of ocular developmental anomalies. Am J Hum Genet (2006) 1.35
Comparison of results of detection of rhinovirus by PCR and viral culture in human nasal wash specimens from subjects with and without clinical symptoms of respiratory illness. J Clin Microbiol (2007) 1.34
A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J (2003) 1.32
Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis (2010) 1.30
Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One (2009) 1.30
Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Nat Commun (2010) 1.29
Involvement of GIGANTEA gene in the regulation of the cold stress response in Arabidopsis. Plant Cell Rep (2005) 1.29
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine (2010) 1.28
Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States. Vaccine (2008) 1.25
Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin (2007) 1.23
Evaluation of smallpox vaccines using variola neutralization. J Gen Virol (2009) 1.21
Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis (2008) 1.21
Implications of the emergence of a novel H1 influenza virus. N Engl J Med (2009) 1.20
Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis (2004) 1.20
Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma. J Allergy Clin Immunol (2005) 1.19
Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther (2003) 1.18
A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. J Infect Dis (2010) 1.18
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One (2013) 1.16
Antigen burden is major determinant of human immunodeficiency virus-specific CD8+ T cell maturation state: potential implications for therapeutic immunization. J Infect Dis (2003) 1.15
Incomplete penetrance and phenotypic variability characterize Gdf6-attributable oculo-skeletal phenotypes. Hum Mol Genet (2009) 1.14
Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation. Clin Infect Dis (2011) 1.13
Exploring nitrilase sequence space for enantioselective catalysis. Appl Environ Microbiol (2004) 1.10
Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One (2009) 1.10
A novel mechanistic spectrum underlies glaucoma-associated chromosome 6p25 copy number variation. Hum Mol Genet (2008) 1.09
Quantitation of metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone after cessation of smokeless tobacco use. Cancer Res (2002) 1.09
Poxvirus zoonoses--putting pocks into context. N Engl J Med (2004) 1.05
Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J (2012) 1.01
Effectiveness and toxicities of intensity-modulated radiotherapy for patients with locally recurrent nasopharyngeal carcinoma. PLoS One (2013) 1.01
Antibody responses to vaccinia membrane proteins after smallpox vaccination. J Infect Dis (2007) 0.99
Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses. Sci Transl Med (2013) 0.99
The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J (2010) 0.97
Novel microneutralization assay for HCMV using automated data collection and analysis. J Immunol Methods (2007) 0.96
A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine (2009) 0.96
Modeling measured glottal volume velocity waveforms. Ann Otol Rhinol Laryngol (2003) 0.94
Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J Infect Dis (2002) 0.94
Vaxfectin enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses. Vaccine (2009) 0.94
Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl (2005) 0.93
FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. Radiother Oncol (2007) 0.92
Perimedullary arteriovenous fistulas in pediatric patients: clinical, angiographical, and therapeutic experiences in a series of 19 cases. Childs Nerv Syst (2010) 0.90
Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clin Ther (2012) 0.90
I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration. Hum Gene Ther (2005) 0.90
Switching immunosuppression medications after renal transplantation--a common practice. Nephrol Dial Transplant (2006) 0.89
Minimizing central bile duct injury during radiofrequency ablation: use of intraductal chilled saline perfusion--initial observations from a study in pigs. Radiology (2004) 0.89
Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario. Vaccine (2013) 0.89
Purification, structure, lipid lowering and liver protecting effects of polysaccharide from Lachnum YM281. Carbohydr Polym (2013) 0.89
Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant (2004) 0.88
The use of sialidase therapy for respiratory viral infections. Antiviral Res (2013) 0.88
Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis. BMC Cancer (2013) 0.88
Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines. Clin Vaccine Immunol (2012) 0.88
Transoesophageal echocardiography in monitoring, guiding, and evaluating surgical repair of congenital cardiac malformations in children. Cardiol Young (2007) 0.88
Physical characterization and in vivo evaluation of poloxamer-based DNA vaccine formulations. J Gene Med (2008) 0.87
Nicorandil Protects the Heart from Ischemia/Reperfusion Injury by Attenuating Endoplasmic Reticulum Response-induced Apoptosis Through PI3K/Akt Signaling Pathway. Cell Physiol Biochem (2015) 0.87
Effect of 5-aza-2'-deoxycytidine on immune-associated proteins in exosomes from hepatoma. World J Gastroenterol (2010) 0.87
Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. Vaccine (2005) 0.86
Isolation, purification, and anti-aging activity of melanin from Lachnum singerianum. Appl Biochem Biotechnol (2014) 0.86
The patient-specific brace design and biomechanical analysis of adolescent idiopathic scoliosis. J Biomech Eng (2009) 0.86
Molecular threading and tunable molecular recognition on DNA origami nanostructures. J Am Chem Soc (2013) 0.85
A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. PLoS One (2011) 0.85
IL-2 plasmid electroporation: from preclinical studies to phase I clinical trial. Methods Mol Biol (2008) 0.85
Electrochemically controlled formation and growth of hydrogen nanobubbles. Langmuir (2006) 0.84
[Several monomes from Tripterygium wilfordii inhibit proliferation of glioma cells in vitro]. Ai Zheng (2002) 0.84
A phase III study of late course accelerated hyperfractionated radiotherapy versus conventionally fractionated radiotherapy in patients with nasopharyngeal carcinoma. Am J Clin Oncol (2012) 0.84
Treatment outcome of patients with stages I-II nasopharyngeal carcinoma after late course accelerated hyperfractionation radiotherapy alone. Oral Oncol (2012) 0.84
Infinite models in scoliosis: a review of the literature and analysis of personal experience. Biomed Tech (Berl) (2008) 0.83
Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques. Vaccine (2004) 0.83
II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential. Hum Gene Ther (2005) 0.83